We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Motif Bio Plc | LSE:MTFB | London | Ordinary Share | GB00BVVT4H71 | ORD 0.01P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.50 | 0.40 | 0.55 | - | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
30/10/2018 09:11 | Very nervously now !!!! | philoosh | |
24/10/2018 12:04 | Safe to say this is the most frustrating share i've ever owned. Fingers crossed we see some movement DEC or early JAN. | t-trader | |
17/10/2018 11:09 | I'm holding, nervously..... | philoosh | |
16/10/2018 14:20 | philoosh, No significant news expected until Jan/Feb Cash burn may indicate a placing may be needed before then Broken down through previous support On the plus side only 10 weeks now til the new year when this should start rising on anticipation imo - just have to hold and see | return_of_the_apeman | |
16/10/2018 10:47 | Why is this tanking? | philoosh | |
11/10/2018 22:13 | I’ve seen triple bottoms in porn vids. Very nice | volsung | |
11/10/2018 22:02 | Needs to hold the triple bottom :-《 | return_of_the_apeman | |
09/10/2018 16:45 | 3 weeks after the half year report and hitting 37p , it is back near it’s all time low. And the same in the US! Not promising!!!! | uncleoswald | |
09/10/2018 13:56 | A lot of things have dropped over the last few days. Italy?? | small crow | |
09/10/2018 13:30 | what is the reason for the big drop off over the last few days? | philoosh | |
28/9/2018 14:57 | Obiterdicta. I will align with you as I feel comfortable running with the herd (whatever bias that is called) | hashertu | |
28/9/2018 10:11 | hashertu - good question. My reading of the implications are as follows: 1. The major shareholder won't need to sell to pay down the loan for at least a year - so no drip fed share sales. 2. The lender has done due diligence and sees that the shares are good security for the loan over a 12 month timeframe. The shares are good collateral and there is little risk of the shares not covering the loan principal if the shares need to be sold in a hurry. It's a positive statement if you draw the above inferences from it. I might be subject to confirmation bias though. ;-) OD | obiterdicta | |
28/9/2018 09:57 | How might today's RNS about Amphion impact MTFB? | hashertu | |
28/9/2018 07:36 | Motif Bio plc (AIM/NASDAQ: MTFB) is a clinical-stage biopharmaceutical company focused on developing novel antibiotics designed to be effective against serious and life-threatening infections caused by multi-drug resistant Gram-positive bacteria, including MRSA. The Company's lead product candidate is iclaprim. Following positive results from two Phase 3 trials (REVIVE-1 and REVIVE-2), a New Drug Application (NDA) was submitted to the U.S. Food & Drug Administration (FDA) for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and is now under review, with a PDUFA date of February 13, 2019. More than 3.6 million patients with ABSSSI are hospitalised annually in the U.S. It is estimated that up to 26% of hospitalized ABSSSI patients have renal impairment Not worried about fundraising after approval. With a course of iclaprim to be a minimum of $1,200, that's a potential $1billion of revenues from the US alone per annum I have never been so confident about FDA approval for a new drug as with this submission so it's a binary play for me with exceptional probability of success. Plan to aďd before the new year We shall see. dyor | return_of_the_apeman | |
25/9/2018 14:44 | Its a hold rather than a buy until we have news on the FDA outcome. There will always be a sense of nervousness as we await news I remain very hopeful of a positive outcome and encouraged at the diligence that went into the submission. They have enough cash to get us to February however if it gets the green light I can understand why further fund raising will be required to bring it to market. In addition of course the production of a phase 3 trial will also require substantial funding. | catch007 | |
25/9/2018 11:03 | COMPANY FOR SALE. BUYERS REQUIRED,! Go on have a tilt, you may be lucky. | escapetohome | |
25/9/2018 10:25 | It is disappointing there is no update on the submission to the EMA. | jane deer | |
25/9/2018 10:07 | Company for sale. Thats enough raisings and dilution. | escapetohome | |
25/9/2018 10:01 | From the half year report: " We continue to believe that iclaprim could be a useful agent for HABP. A Phase 3 trial is being planned and commencement remains subject to funding." and "As we near our PDUFA date, we continue to evaluate additional capital raising opportunities to fund our growth and continuing operations...." No matter how much money they raise it never seems to be enough. | bandflex | |
17/9/2018 11:44 | When is this gonna take off? I'm antsy..... | philoosh | |
15/9/2018 07:26 | At all-time low in US!! | uncleoswald | |
06/9/2018 20:51 | Only 5 months and the news may come sooner - expect the circus will arrive on the first trading day of the new year Meanwhile in charty tea leaf land an inverse h&s on the chart points to a retest of 36p, strengthened by the double bottom Wake me up in Feb when this is through the pound barrier | return_of_the_apeman | |
03/9/2018 06:38 | Sbtx RNS boom time.Big rerate to come | costax1654x | |
22/8/2018 08:28 | Being played like a bloody fiddle. Still, only 6 months to go now | l4z4rus |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions